11/01/2019, 14:00 - 15:00 in MAP/0G/006
Lamrock, Felicity (Trinity College Dublin)
The National Centre for Pharmacoeconomics (NCPE) assesses the cost-effectiveness of new drugs for which reimbursement by the healthcare payer the Health Service Executive (HSE) is sought in Ireland. All new drugs seeking reimbursement in Ireland are subjected to a preliminary rapid review by the NCPE. Drugs which are high in cost or have a significant budget impact are required to subsequently complete a full Health Technology Assessment (HTA). A full HTA involves a systematic, evidence-based assessment of the comparative effectiveness, cost-effectiveness and potential budget impact of drugs for use by patients in Ireland. The HTAs are critically appraised by the Review Group (RG) at the NCPE. The RG consists of clinical, statistical and health economic expertise. The cost-effectiveness models submitted with a HTA contains several statistical aspects such as survival analysis, health economic modelling, and evidence synthesis. This talk describes some of these components in detail, as well as providing examples of issues that commonly occur.